MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells $231,878.33 in Stock

MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Alexandria Forbes sold 35,839 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total transaction of $231,878.33. Following the completion of the sale, the chief executive officer now directly owns 1,395,102 shares of the company’s stock, valued at approximately $9,026,309.94. The trade was a 2.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

MeiraGTx Trading Down 2.4 %

NASDAQ:MGTX traded down $0.15 on Friday, reaching $6.20. 463,403 shares of the company’s stock were exchanged, compared to its average volume of 307,667. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $484.55 million, a price-to-earnings ratio of -5.12 and a beta of 1.26. The business has a fifty day moving average of $6.28 and a 200-day moving average of $5.12. MeiraGTx Holdings plc has a 52-week low of $3.85 and a 52-week high of $7.37.

Institutional Trading of MeiraGTx

A number of institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company increased its stake in MeiraGTx by 19.0% during the second quarter. The Manufacturers Life Insurance Company now owns 17,763 shares of the company’s stock worth $75,000 after purchasing an additional 2,839 shares during the period. JPMorgan Chase & Co. increased its stake in shares of MeiraGTx by 1.2% during the third quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock worth $1,429,000 after buying an additional 4,186 shares during the period. Rhumbline Advisers increased its stake in shares of MeiraGTx by 10.8% during the second quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock worth $223,000 after buying an additional 5,178 shares during the period. State Street Corp increased its stake in shares of MeiraGTx by 0.9% during the third quarter. State Street Corp now owns 574,727 shares of the company’s stock worth $2,397,000 after buying an additional 5,251 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of MeiraGTx by 142.5% during the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock worth $39,000 after buying an additional 5,476 shares during the period. 67.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada upped their target price on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and set a $36.00 price target on shares of MeiraGTx in a research report on Monday, November 18th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.